Population Pharmacokinetics of Matuzumab in Cancer Patients
Author Information
Author(s): Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C
Primary Institution: Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany
Hypothesis
To develop a population pharmacokinetic model for matuzumab, a humanised monoclonal antibody, including a covariate analysis.
Conclusion
A robust population pharmacokinetic model for matuzumab was developed, which can guide dose selection for this targeted cancer therapy.
Supporting Evidence
- The model was developed using over 1200 serum concentration data points.
- A covariate analysis identified weight as influencing pharmacokinetic parameters.
- The study included patients with advanced, nonresectable, and/or metastatic carcinoma.
Takeaway
This study looked at how the drug matuzumab behaves in the body of cancer patients, helping doctors decide the best dose to give.
Methodology
The study analyzed serum concentration data from 90 patients using a two-compartment model with nonlinear elimination pathways.
Potential Biases
Potential bias due to the nonrandomized and uncontrolled nature of the studies.
Limitations
The study was limited to three phase I studies and included only patients with advanced carcinoma.
Participant Demographics
53 males and 37 females, aged 29 to 82 years, with various types of advanced carcinoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website